Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) in Newly Diagnosed Multiple Myeloma (NDMM): Outcomes in Patients with 1q21⁺ Status in the Phase 3 IMROZ Study

Presented by Dr. Thomas Martin, this IMROZ subgroup analysis demonstrated that adding isatuximab to standard VRd therapy improved progression-free survival and deepened responses in transplant-ineligible patients with newly diagnosed multiple myeloma and 1q21+ status, a high-risk cytogenetic subgroup.

Related Content:

Rapid Readouts

Favorable Benefit-Risk Profile of Avapritinib in Indolent Systemic Mastocytosis Is Maintained After 3 Years of Therapy: Longer-Term Analysis of the PIONEER Study

Lurbinectedin + Atezolizumab as First-Line Maintenance Treatment in Patients With Extensive-Stage Small Cell Lung Cancer: Primary Results of the Phase 3 IMforte Trial

A First-in-Human, Phase 1a/b, Dose-Escalation/Expansion Study of BG-68501, a Selective CDK2 Inhibitor, as Monotherapy or in Combination With Fulvestrant for Patients With HR+/HER2– Breast Cancer and Other Advanced Solid Tumors: First Disclosure of Clinical Data